Literature DB >> 22829303

Comments on Reinhart et al.: consensus statement of the ESICM task force on colloid volume therapy in critically ill patients.

Kai Zacharowski, H Van Aken, Gernot Marx, Matthias Jacob, Walter Schaffartzik, Michael Zenz, S A Loer, Can Ince, Claude Martin, Stefan De Hert, Markus W Hollmann, Armand R J Girbes, Sybille Kozek-Langenecker, Hans Gombotz, Bertrand Guidet, Giorgio Della Rocca, Jonathan Wilson, Andrea De Gasperi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22829303      PMCID: PMC3423567          DOI: 10.1007/s00134-012-2639-4

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
Dear Editor, We are grateful that a task force has addressed colloid volume therapy in critically ill patients [1]. This issue is currently the focus of considerable debate, and new data from ongoing trials can be expected in the new future. A task force is considered to be a group of specialists who have been appointed to work together on a temporary basis with the specific aim to provide an answer to a specific question. In this respect, the consensus statement of the European Society of Intensive Care Medicine’s task force on colloid volume replacement in critically ill patients immediately raises two questions: what is the basis on which the task force was selected? Which entity initiated this initiative? The methodology of the article does not provide any information on these points, and the reader is left with some degree of doubt on how the individual members of the “task force” were selected. Eight individuals (“the eight panel members”) apparently voted on each aspect of the statement. However, it seems highly questionable whether a small group of only eight individuals are capable of representing a true consensus of the various opinions among experts in the field in Europe—particularly when the group included two authors from the same department, representing 25 % of the votes. Our concern is not whether the statement is correct or incorrect, but rather whether the approach used to establish the consensus was the most suitable one and whether it was capable of representing the opinions of intensivists throughout Europe—particularly since current data on the topic are limited, and several trials currently in progress are likely to provide new data in the very near future. Was the methodology for drawing up guidelines on best medical practices—as recommended by the European Health Committee (Comité Européen de la Santé, CDSP) and adopted by the Committee of Ministers of the Council of Europe in 2001 [2]—followed during the review process and publication of the statement? It is therefore very surprising that such an important statement was apparently accepted for publication by Intensive Care Medicine within 2 days of submission (as specified on p. 368). In the absence of any information on how the present recommendations were evaluated, the reader can only speculate on the peer review process regarding this consensus statement. Are these recommendations supported by the majority of European intensive care specialists or do they merely reflect the “expert opinion” of eight authors? Here, we suggest that these points need to be clarified. In future comparable cases, we would also recommend that such statements should be based on the input of representatives of all of the disciplines involved in critical care medicine (surgery, anesthesia, internal medicine, neurology, physiology, etc.). Such an approach, based on a comprehensible procedure, is currently being used in Germany to develop a guideline on intravascular volume therapy in adults, in accordance with the guidelines of the Working Group of Scientific Medical Specialist Societies (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) [3].
  1 in total

1.  Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients.

Authors:  Konrad Reinhart; Anders Perner; Charles L Sprung; Roman Jaeschke; Frederique Schortgen; A B Johan Groeneveld; Richard Beale; Christiane S Hartog
Journal:  Intensive Care Med       Date:  2012-02-10       Impact factor: 17.440

  1 in total
  6 in total

1.  A farewell editorial and a final balance.

Authors:  Massimo Antonelli
Journal:  Intensive Care Med       Date:  2013-01-18       Impact factor: 17.440

2.  Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients: editors' reply to Zacharowski et al.

Authors:  Massimo Antonelli; Salvatore Maurizio Maggiore
Journal:  Intensive Care Med       Date:  2012-07-25       Impact factor: 17.440

3.  A Prospective Observational Study of Rational Fluid Therapy in Asian Intensive Care Units: Another Puzzle Piece in Fluid Therapy.

Authors:  Matthias Jacob; Sambit Sahu; Yogendra P Singh; Yatin Mehta; Kuang-Yao Yang; Shuenn-Wen Kuo; Farooq Memom; Shirish Prayag; Rajesh Pande; Nirmal Jaiswal; Tan C Cheng; Amit Mandal; Shanti R Deva; Mohan Mathew; Nagarajan Ramakrishnan; Vineya Rai; Luah Wah; Gopinath Ramachandran; Rajesh Chawla; Z A Khan; J V Divatia; Rajesh Mishra; Pravin Amin; Jayant Shelgaokar; Bernhard Zwissler; Hugo Van Aken; Christian Ertmer
Journal:  Indian J Crit Care Med       Date:  2020-11

4.  Hydroxyethyl starch - the importance of being earnest.

Authors:  Daniel Chappell; Matthias Jacob
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2013-08-09       Impact factor: 2.953

5.  Factors influencing lengths of stay in the intensive care unit for surviving trauma patients: a retrospective analysis of 30,157 cases.

Authors:  Andreas B Böhmer; Katja S Just; Rolf Lefering; Thomas Paffrath; Bertil Bouillon; Robin Joppich; Frank Wappler; Mark U Gerbershagen
Journal:  Crit Care       Date:  2014-07-07       Impact factor: 9.097

6.  Fluid therapy and outcome: a prospective observational study in 65 German intensive care units between 2010 and 2011.

Authors:  Christian Ertmer; Bernhard Zwißler; Hugo Van Aken; Michael Christ; Fabian Spöhr; Axel Schneider; Robert Deisz; Matthias Jacob
Journal:  Ann Intensive Care       Date:  2018-02-17       Impact factor: 6.925

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.